This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alnylam Presents New Pre-clinical Data On Subcutaneously Delivered RNAi Therapeutics For Cardiovascular Metabolic Disease At Arteriosclerosis, Thrombosis And Vascular Biology 2014 Scientific Sessions

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from RNAi therapeutic programs toward genetically validated targets in cardiovascular metabolic diseases, including ALN-PCSsc targeting PCSK9 for the treatment of hypercholesterolemia, and a newly named program, ALN-AC3, targeting apolipoprotein C-III (apoCIII) for the treatment of hypertriglyceridemia. These data are being presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions being held May 1-3 in Toronto, Ontario. In an oral presentation titled “ A Subcutaneous, Potent and Durable RNAi Platform Targeting Metabolic Diseases, Genes PCSK9, ApoCIII and ANGPLT3” new pre-clinical data utilizing the company’s GalNAc-siRNA conjugate platform demonstrated robust and durable knockdown of these key cardiovascular metabolic disease targets. Amongst other data, Alnylam presented new single-dose durability data for ALN-PCSsc showing robust knockdown of PCSK9 and reductions in LDL-C that support once-monthly and possibly once-quarterly subcutaneous dosing regimens. Specifically, a single dose of ALN-PCSsc maintained greater than 50% LDL-C reductions for over three months in the absence of statin co-administration. The company plans to file an investigational new drug (IND) application, or IND equivalent, for ALN-PCSsc by late 2014 or early 2015.

“As evidenced by these data presented at ATVB, we are building the beginnings of a promising pipeline of RNAi therapeutics toward genetically validated disease targets in the cardio-metabolic space. We see this as an attractive area for continued investment for Alnylam given the large number of liver-expressed disease-causing genes and the emerging profile of our GalNAc-conjugate platform enabling subcutaneous delivery with potent disease gene knockdown, a wide therapeutic index, and highly durable effects. These features are exemplified with ALN-PCSsc, where new non-human primate pre-clinical results demonstrate significant knockdown of PCSK9 and reductions in LDL-C with very durable effects, lasting over three months. We believe that this level of durability should readily support a once-monthly and possibly a once-quarterly subcutaneous dosing regimen, and thus represents what should be a highly competitive profile with anti-PCSK9 monoclonal antibodies. We look forward to advancing ALN-PCSsc toward clinical trials by the end of this year or early next,” said Kevin Fitzgerald, Ph.D., Senior Director, Research at Alnylam. “In addition, new rodent data with ALN-AC3, our GalNAc-siRNA conjugate targeting apoCIII, showed up to 95% knockdown of ApoCIII and up to 68% reduction in triglycerides. These pre-clinical results warrant further efforts to advance this new RNAi therapeutic program into later stages of development.”

1 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs